Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-3
2025-523769-11-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of eloralintide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight. Planned start Mar 2026; status: authorised.
02
Drugs
eloralintide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on 2025-523769-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523769-11-00.